{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-25-000012","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.877172+00:00","generated_at":"2026-05-25T15:00:49.847566+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Instil Bio Q4 net loss $1.82/sh; cash $115.1M; AXN-2510 NSCLC data expected 1H2025","bullets":["GAAP net loss per share $1.82 in Q4, full year $11.39; non-GAAP $1.08 and $7.59 respectively.","Cash, equivalents, restricted cash and marketable securities $115.1M at Dec 31, 2024, down from $175.0M year-end 2023; runway beyond 2026.","Clinical data for AXN-2510 (PD-L1xVEGF bispecific) monotherapy in R/R NSCLC anticipated 1H2025; safety data across ~100 patients.","ImmuneOnco to initiate 1L NSCLC patient enrollment in China Phase 1b/2 trial of AXN-2510 plus chemo in Q2 2025; US trial expected before end of 2025.","R&D expenses $1.1M Q4 (vs $2.0M prior year); G&A $10.4M Q4; restructuring charges $0.3M Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-25-000012","json":"https://secwatch.observer/filing/0001789769-25-000012.json","markdown":"https://secwatch.observer/filing/0001789769-25-000012.md","text":"https://secwatch.observer/filing/0001789769-25-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000012/0001789769-25-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000012/til-20250304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T15:00:49.847566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}